These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12193713)

  • 21. Disulfide reduction in major histocompatibility complex class II-restricted antigen processing by interferon-gamma-inducible lysosomal thiol reductase.
    Phan UT; Maric M; Cresswell P
    Methods Enzymol; 2002; 348():43-8. PubMed ID: 11885292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Negligible class II MHC presentation of B cell receptor-derived peptides by high density resting B cells.
    Snyder CM; Zhang X; Wysocki LJ
    J Immunol; 2002 Apr; 168(8):3865-73. PubMed ID: 11937540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reduction of disulfide bonds during antigen processing: evidence from a thiol-dependent insulin determinant.
    Jensen PE
    J Exp Med; 1991 Nov; 174(5):1121-30. PubMed ID: 1940793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo.
    Qi L; Rojas JM; Ostrand-Rosenberg S
    J Immunol; 2000 Nov; 165(10):5451-61. PubMed ID: 11067897
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New insights in antigen processing and epitope selection: development of novel immunotherapeutic strategies for cancer, autoimmunity and infectious diseases.
    Haque A; Blum JS
    J Biol Regul Homeost Agents; 2005; 19(3-4):93-104. PubMed ID: 16602623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Large cytoplasmic inclusion body kappa-chain has unusual intrachain disulfide bonding.
    Jäck HM; Sloan B; Grisham G; Reason D; Wabl M
    J Immunol; 1993 Jun; 150(11):4928-33. PubMed ID: 8388424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antigen three-dimensional structure guides the processing and presentation of helper T-cell epitopes.
    Carmicle S; Steede NK; Landry SJ
    Mol Immunol; 2007 Feb; 44(6):1159-68. PubMed ID: 16893568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interchain disulfide bonding in human IgG2 antibodies probed by site-directed mutagenesis.
    Allen MJ; Guo A; Martinez T; Han M; Flynn GC; Wypych J; Liu YD; Shen WD; Dillon TM; Vezina C; Balland A
    Biochemistry; 2009 May; 48(17):3755-66. PubMed ID: 19254029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of the C-terminal propeptide in the activity and maturation of gamma -interferon-inducible lysosomal thiol reductase (GILT).
    Phan UT; Lackman RL; Cresswell P
    Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12298-303. PubMed ID: 12198183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cutting edge: induction of the antigen-processing enzyme IFN-gamma-inducible lysosomal thiol reductase in melanoma cells Is STAT1-dependent but CIITA-independent.
    O'Donnell PW; Haque A; Klemsz MJ; Kaplan MH; Blum JS
    J Immunol; 2004 Jul; 173(2):731-5. PubMed ID: 15240658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD4+ T-cell epitope prediction using antigen processing constraints.
    Mettu RR; Charles T; Landry SJ
    J Immunol Methods; 2016 May; 432():72-81. PubMed ID: 26891811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes.
    Schirmbeck R; Stober D; El-Kholy S; Riedl P; Reimann J
    J Immunol; 2002 Jun; 168(12):6253-62. PubMed ID: 12055239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of an altered peptide ligand based on the endogenously presented, rheumatoid arthritis-associated, human cartilage glycoprotein-39(263-275) epitope: an MHC anchor variant peptide for immune modulation.
    Boots AM; Hubers H; Kouwijzer M; den Hoed-van Zandbrink L; Westrek-Esselink BM; van Doorn C; Stenger R; Bos ES; van Lierop MJ; Verheijden GF; Timmers CM; van Staveren CJ
    Arthritis Res Ther; 2007; 9(4):R71. PubMed ID: 17645792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages.
    Tsark EC; Wang W; Teng YC; Arkfeld D; Dodge GR; Kovats S
    J Immunol; 2002 Dec; 169(11):6625-33. PubMed ID: 12444176
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential requirements for endosomal reduction in the presentation of two H2-E(d)-restricted epitopes from influenza hemagglutinin.
    Sinnathamby G; Maric M; Cresswell P; Eisenlohr LC
    J Immunol; 2004 Jun; 172(11):6607-14. PubMed ID: 15153475
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions.
    Godkin AJ; Smith KJ; Willis A; Tejada-Simon MV; Zhang J; Elliott T; Hill AV
    J Immunol; 2001 Jun; 166(11):6720-7. PubMed ID: 11359828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal IgG as antigens: reduction is an early intracellular event of their processing by antigen-presenting cells.
    Santoro L; Reboul A; Kerblat I; Drouet C; Colomb MG
    Int Immunol; 1996 Feb; 8(2):211-9. PubMed ID: 8671606
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues.
    Vertuani S; Sette A; Sidney J; Southwood S; Fikes J; Keogh E; Lindencrona JA; Ishioka G; Levitskaya J; Kiessling R
    J Immunol; 2004 Mar; 172(6):3501-8. PubMed ID: 15004150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility complex class I molecules.
    Niedermann G; Butz S; Ihlenfeldt HG; Grimm R; Lucchiari M; Hoschützky H; Jung G; Maier B; Eichmann K
    Immunity; 1995 Mar; 2(3):289-99. PubMed ID: 7535183
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The role of the MHC class II transactivator in class II expression and antigen presentation by astrocytes and in susceptibility to central nervous system autoimmune disease.
    Stüve O; Youssef S; Slavin AJ; King CL; Patarroyo JC; Hirschberg DL; Brickey WJ; Soos JM; Piskurich JF; Chapman HA; Zamvil SS
    J Immunol; 2002 Dec; 169(12):6720-32. PubMed ID: 12471103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.